 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 GLOBE NEWSWIRE -- ADMA Biologics, Inc. Nasdaq: ADMA, an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Centers for Medicare and Medicaid Services CMS has approved transitional pass-through payment status and established a new reimbursement C-code, C9072, for ASCENIV which is effective January 1, 2021. 